11月6日,梯瓦制药(TEVA)股价盘中重挫逾6%,引发市场关注。对于股价暴跌的原因,目前尚无明确说法。
梯瓦制药CEO理查德-弗朗西斯此前透露,公司将与即将上任的特朗普政府开展良好合作,但尚不确定特朗普政府未来在医疗保健和制药行业的具体政策走向。一些分析人士认为,投资者对特朗普政府的政策前景存在不确定性,或令梯瓦制药遭到不利影响,从而引发资金流出并拖累股价表现。
不过,梯瓦制药当季业绩表现强劲,且分析师看好公司未来几年品牌药、仿制药和生物仿制药产品线的增长前景。毫无疑问,特朗普政府的政策导向将是影响梯瓦制药后续股价走势的重要因素。我们将持续关注该公司的后续动态,以及相关政策的推进情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.